Literature DB >> 3100510

Treatment of major affective disorder with fluvoxamine.

Y D Lapierre, M Browne, E Horn, L K Oyewumi, D Sarantidis, N Roberts, K Badoe, P Tessier.   

Abstract

A placebo-controlled, double-blind study of 63 inpatients with major affective disorder was performed to compare the safety and efficacy of fluvoxamine and imipramine. Results indicate that fluvoxamine and imipramine are superior to placebo and demonstrate a trend toward superiority of fluvoxamine over imipramine. Fluvoxamine was generally well tolerated in most patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3100510

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

Review 1.  Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications.

Authors:  Hans Melander; Jane Ahlqvist-Rastad; Gertie Meijer; Björn Beermann
Journal:  BMJ       Date:  2003-05-31

2.  A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients.

Authors:  Walter W van den Broek; Tom K Birkenhäger; Paul G H Mulder; Jan A Bruijn; Peter Moleman
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

3.  Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis.

Authors:  E Trindade; D Menon; L A Topfer; C Coloma
Journal:  CMAJ       Date:  1998-11-17       Impact factor: 8.262

4.  Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis.

Authors:  I M Anderson; B M Tomenson
Journal:  BMJ       Date:  1995-06-03

Review 5.  Fluvoxamine versus other anti-depressive agents for depression.

Authors:  Ichiro M Omori; Norio Watanabe; Atsuo Nakagawa; Andrea Cipriani; Corrado Barbui; Hugh McGuire; Rachel Churchill; Toshi A Furukawa
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

Review 6.  Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis.

Authors:  Barbara Nussbaumer; Laura C Morgan; Ursula Reichenpfader; Amy Greenblatt; Richard A Hansen; Megan Van Noord; Linda Lux; Bradley N Gaynes; Gerald Gartlehner
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

7.  Antidepressant response and fluvoxamine plasma concentrations: a pilot study.

Authors:  Florence Schwarzenbach; Christian Netillard; Patricia Demoly; Dorothé Bisschop; Samuel Limat; Serge Bouquet; Sylvette Vandel; Anne-Marie Bel; Marie-Christine Woronoff-Lemsi
Journal:  Pharm World Sci       Date:  2003-02

Review 8.  Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.

Authors:  M I Wilde; G L Plosker; P Benfield
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 9.  Comparative efficacy of antidepressants.

Authors:  S Kasper; J Fuger; H J Möller
Journal:  Drugs       Date:  1992       Impact factor: 9.546

10.  Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.

Authors:  F Song; N Freemantle; T A Sheldon; A House; P Watson; A Long; J Mason
Journal:  BMJ       Date:  1993-03-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.